日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)

在早期乳腺癌患者中,帕博西尼联合辅助内分泌治疗的 PALLAS 随机试验中的生活质量和症状严重程度(AFT-05、ABCSG-42、BIG-14-03、PrE0109)

Naughton, M J; Zahrieh, D M; Gnant, M; Zdenkowski, N; Lemieux, J; Mao, J J; Bjelic-Radisic, V; Shinn, E; Balic, M; Thomssen, C; Meisel, J L; Ruiz, G M; Loibl, S; Isaacs, C; Cameron, D; Henao-Carrasco, F M; Goetz, M P; Singer, C F; Werutsky, G; Rugo, H S; Vetter, M; Tseng, L-M; Miller, K; Fitzal, F; Gil Gil, J M; Park, H; Linderholm, B; Bajetta, E; Dayao, Z; Prat, A; Ehrhardt, K; Metzger, O; Arahmani, A; Law, E H; Partridge, A H; Carey, L A; Zoroufy, A; Dueck, A C; O'Brien, P; Hlauschek, D; DeMichele, A; Mayer, E L

Advancing equitable access to innovation in breast cancer

促进乳腺癌创新成果的公平获取

O'Reilly, Seamus; Luis, Ines Vaz; Adam, Virginie; Razis, Evangelia D; Urruticoechea, Ander; Arahmani, Amal; Carrasco, Eva; Chua, Boon H; Bliss, Judith; Straehle, Carolyn; Goulioti, Theodora; Lindholm, Barbro; Werutsky, Gustavo; Brain, Etienne; Bedard, Philippe L; Curigliano, Giuseppe; Loi, Sherene; Saji, Shigehira; Cameron, David

Author Correction: Advancing equitable access to innovation in breast cancer

作者更正:推进乳腺癌创新成果的公平获取

O'Reilly, Seamus; Luis, Ines Vaz; Adam, Virginie; Razis, Evangelia D; Urruticoechea, Ander; Arahmani, Amal; Carrasco, Eva; Chua, Boon H; Bliss, Judith; Straehle, Carolyn; Goulioti, Theodora; Lindholm, Barbro; Werutsky, Gustavo; Brain, Etienne; Bedard, Philippe L; Curigliano, Giuseppe; Loi, Sherene; Saji, Shigehira; Cameron, David

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

OlympiA III期临床试验中,奥拉帕尼辅助治疗对携带BRCA1/2种系致病性变异的高危早期乳腺癌患者的总生存期

Geyer, C E Jr; Garber, J E; Gelber, R D; Yothers, G; Taboada, M; Ross, L; Rastogi, P; Cui, K; Arahmani, A; Aktan, G; Armstrong, A C; Arnedos, M; Balmaña, J; Bergh, J; Bliss, J; Delaloge, S; Domchek, S M; Eisen, A; Elsafy, F; Fein, L E; Fielding, A; Ford, J M; Friedman, S; Gelmon, K A; Gianni, L; Gnant, M; Hollingsworth, S J; Im, S-A; Jager, A; Jóhannsson, Ó Þ; Lakhani, S R; Janni, W; Linderholm, B; Liu, T-W; Loman, N; Korde, L; Loibl, S; Lucas, P C; Marmé, F; Martinez de Dueñas, E; McConnell, R; Phillips, K-A; Piccart, M; Rossi, G; Schmutzler, R; Senkus, E; Shao, Z; Sharma, P; Singer, C F; Španić, T; Stickeler, E; Toi, M; Traina, T A; Viale, G; Zoppoli, G; Park, Y H; Yerushalmi, R; Yang, H; Pang, D; Jung, K H; Mailliez, A; Fan, Z; Tennevet, I; Zhang, J; Nagy, T; Sonke, G S; Sun, Q; Parton, M; Colleoni, M A; Schmidt, M; Brufsky, A M; Razaq, W; Kaufman, B; Cameron, D; Campbell, C; Tutt, A N J

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

APHINITY研究中患者报告的功能、健康相关生活质量和症状:帕妥珠单抗联合曲妥珠单抗和化疗治疗HER2阳性早期乳腺癌

Bines, José; Clark, Emma; Barton, Claire; Restuccia, Eleonora; Procter, Marion; Sonnenblick, Amir; Fumagalli, Debora; Parlier, Damien; Arahmani, Amal; Baselga, José; Viale, Giuseppe; Reaby, Linda L; Frank, Elizabeth; Gelber, Richard D; Piccart, Martine; Jackisch, Christian; Petersen, Jennifer A

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

早期 HER2 阳性乳腺癌辅助治疗:帕妥珠单抗和曲妥珠单抗

von Minckwitz, Gunter; Procter, Marion; de Azambuja, Evandro; Zardavas, Dimitrios; Benyunes, Mark; Viale, Giuseppe; Suter, Thomas; Arahmani, Amal; Rouchet, Nathalie; Clark, Emma; Knott, Adam; Lang, Istvan; Levy, Christelle; Yardley, Denise A; Bines, Jose; Gelber, Richard D; Piccart, Martine; Baselga, Jose